2022
TRAIL Score: A Simple Model to Predict Immunochemotherapy Tolerability in Patients With Diffuse Large B-Cell Lymphoma
Harris W, Bataillard E, Choi Y, El-Galaly T, Cuchelkar V, Henneges C, Kwan A, Schneider D, Paulson J, Nielsen T. TRAIL Score: A Simple Model to Predict Immunochemotherapy Tolerability in Patients With Diffuse Large B-Cell Lymphoma. JCO Clinical Cancer Informatics 2022, 6: e2100121. PMID: 35044836, DOI: 10.1200/cci.21.00121.Peer-Reviewed Original ResearchConceptsDiffuse large B-cell lymphomaLarge B-cell lymphomaB-cell lymphomaR-CHOPFirst-line treatment of diffuse large B-cell lymphomaDiagnosed DLBCLTreatment of diffuse large B-cell lymphomaCourses of R-CHOPPresence of cardiovascular diseaseFirst-line treatmentProportion of patientsArea under the curveRoutine clinical settingCharlson Comorbidity IndexStandard of careHigh-risk categoryStandard chemoimmunotherapyChemotherapy toxicityCreatinine clearanceInferior outcomesBaseline characteristicsLogistic regression modelsComorbidity indexPatient frailtyEnd points
2020
The Combination of High Total Metabolic Tumor Volume and Poor ECOG Performance Status Defines Ultra-High Risk Diffuse Large B-Cell Lymphoma. Validation across Multiple Cohorts of Large Clinical Trials and in Real World
Thieblemont C, Chartier L, Dührsen U, Vitolo U, Barrington S, Vercellino L, Zaucha J, Carvalho I, da Silva Maria G, Decazes P, Viailly P, Tilly H, Berriolo-Riedinger A, Casasnovas R, Hüttmann A, Ilyas H, Mikhaeel G, Dunn J, Cottereau A, Schmitz C, Paulson J, Nielsen T, Meignan M. The Combination of High Total Metabolic Tumor Volume and Poor ECOG Performance Status Defines Ultra-High Risk Diffuse Large B-Cell Lymphoma. Validation across Multiple Cohorts of Large Clinical Trials and in Real World. Blood 2020, 136: 30-31. DOI: 10.1182/blood-2020-136544.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaLarge B-cell lymphomaMetabolic tumor volumeProgression-free survivalB-cell lymphomaClinical trialsR-CHOPOverall survivalTumor volumeNewly diagnosed diffuse large B-cell lymphomaTotal metabolic tumor volumeStandard of careECOG PSCurative intentImmuno-chemotherapyPatientsMultiple centersEarly identificationCohortLymphomaTrialsSurvivalMultiple cohortsBaselineTMTV